DE69226447D1 - NMDA Antagonisten - Google Patents

NMDA Antagonisten

Info

Publication number
DE69226447D1
DE69226447D1 DE69226447T DE69226447T DE69226447D1 DE 69226447 D1 DE69226447 D1 DE 69226447D1 DE 69226447 T DE69226447 T DE 69226447T DE 69226447 T DE69226447 T DE 69226447T DE 69226447 D1 DE69226447 D1 DE 69226447D1
Authority
DE
Germany
Prior art keywords
halo
formula
nmda antagonists
epilepsy
anxiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69226447T
Other languages
English (en)
Other versions
DE69226447T2 (de
Inventor
Michael G Palfreyman
Francesco G Salituro
Ian A Mcdonald
Robert Schwarcz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of DE69226447D1 publication Critical patent/DE69226447D1/de
Application granted granted Critical
Publication of DE69226447T2 publication Critical patent/DE69226447T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69226447T 1991-02-28 1992-02-24 NMDA Antagonisten Expired - Lifetime DE69226447T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66267091A 1991-02-28 1991-02-28

Publications (2)

Publication Number Publication Date
DE69226447D1 true DE69226447D1 (de) 1998-09-03
DE69226447T2 DE69226447T2 (de) 1999-04-22

Family

ID=24658685

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69226447T Expired - Lifetime DE69226447T2 (de) 1991-02-28 1992-02-24 NMDA Antagonisten
DE69201141T Expired - Lifetime DE69201141T2 (de) 1991-02-28 1992-02-24 NMDA-Antagonisten.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69201141T Expired - Lifetime DE69201141T2 (de) 1991-02-28 1992-02-24 NMDA-Antagonisten.

Country Status (15)

Country Link
EP (2) EP0624569B1 (de)
JP (1) JP3168566B2 (de)
KR (2) KR100237264B1 (de)
AT (2) ATE168989T1 (de)
AU (2) AU643365B2 (de)
CA (1) CA2061836C (de)
DE (2) DE69226447T2 (de)
DK (2) DK0624569T3 (de)
ES (2) ES2122098T3 (de)
FI (1) FI920880A (de)
GR (1) GR3015130T3 (de)
HU (1) HU213214B (de)
IE (2) IE65728B1 (de)
NO (1) NO178727C (de)
NZ (1) NZ241718A (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2115442C (en) * 1991-09-09 2003-09-23 Christopher Franklin Bigge Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5519055A (en) * 1993-08-06 1996-05-21 University Of Maryland At Baltimore Substituted kynurenines and process for their preparation
US5786508A (en) * 1994-07-15 1998-07-28 Pharmacia & Upjohn S.P.A. Substituted kynurenines and process for their preparation
GB9521486D0 (en) * 1995-10-20 1995-12-20 Pharmacia Spa Fluoro-substituted benzoylpropionic acid derivatives
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
EP1964835A1 (de) * 2007-02-28 2008-09-03 Centre National de la Recherche Scientifique Derivate von Psammaplin A, Verfahren zu ihrer Synthese und ihre Verwendung für die Vorbeugung oder Behandlung von Krebs
KR101308507B1 (ko) * 2011-07-07 2013-09-17 (주)비알뷰티플레볼루션 트립토판을 함유하는 여드름 치료제 및 피지분비 억제제, 및 이를 포함하는 광역학적 치료용 키트
WO2017065899A1 (en) * 2015-10-16 2017-04-20 Auspex Pharmaceuticals, Inc. Deuterated chlorokynurenines for the treatment of neuropsychiatric disorders
EP3427729A1 (de) * 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid zur behandlung von epileptischen erkrankungen, störungen oder zuständen
CN118026866A (zh) 2018-02-09 2024-05-14 维斯塔津治疗公司 4-氯代犬尿氨酸及中间体的合成

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1179866B (it) * 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
IT1206078B (it) * 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
IT1237472B (it) * 1989-10-04 1993-06-07 Polifarma Spa Derivati di acido 3-indolpiruvico, loro procedimento di produzione ed impiego terapeutico.
DE19502075A1 (de) * 1995-01-24 1996-07-25 Grohe Armaturen Friedrich Auslaufarmatur mit Befestigungseinrichtung

Also Published As

Publication number Publication date
NO920784L (no) 1992-08-31
FI920880A0 (fi) 1992-02-27
CA2061836A1 (en) 1992-08-29
EP0624569B1 (de) 1998-07-29
EP0624569A1 (de) 1994-11-17
IE920631A1 (en) 1992-09-09
NO178727C (no) 1996-05-22
ATE116969T1 (de) 1995-01-15
AU1114492A (en) 1992-09-03
KR100261933B1 (ko) 2000-07-15
AU4497593A (en) 1993-11-18
KR100237264B1 (ko) 2000-02-01
CA2061836C (en) 2006-05-02
IE80774B1 (en) 1999-02-10
GR3015130T3 (en) 1995-05-31
NO178727B (no) 1996-02-12
DE69201141D1 (de) 1995-02-23
ES2069921T3 (es) 1995-05-16
IE65728B1 (en) 1995-11-15
HU213214B (en) 1997-03-28
NO920784D0 (no) 1992-02-27
ATE168989T1 (de) 1998-08-15
ES2122098T3 (es) 1998-12-16
DK0624569T3 (da) 1998-10-26
DE69201141T2 (de) 1995-05-11
JPH0586027A (ja) 1993-04-06
EP0501378A1 (de) 1992-09-02
DE69226447T2 (de) 1999-04-22
NZ241718A (en) 1994-07-26
HU9200658D0 (en) 1992-05-28
JP3168566B2 (ja) 2001-05-21
FI920880A (fi) 1992-08-29
HUT67033A (en) 1995-01-30
DK0501378T3 (da) 1995-03-20
KR920016418A (ko) 1992-09-24
EP0501378B1 (de) 1995-01-11
AU643365B2 (en) 1993-11-11
AU656278B2 (en) 1995-01-27

Similar Documents

Publication Publication Date Title
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
BRPI0409109A (pt) novos compostos
DE69226447T2 (de) NMDA Antagonisten
BR0208468A (pt) Camsilato de amlodipina e processo para sua preparação
CY1119257T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda)
ES2051834T3 (es) El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad.
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
ES2082882T3 (es) Procedimiento para la fabricacion de derivados de acidos-3-amino-2-(het)aroil-acrilicos.
DK526087A (da) Antikonvulsive aminosyrederivater
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
ES2169723T3 (es) Derivados de piridinio y su uso para determinar trastornos del tejido conectivo en seres humanos y animales.
DE3880304T2 (de) 2-hydroxy-3-aryloxy-propylaminderivate mit kardiovaskulaerer wirkung.
ES2062214T3 (es) Derivados de aminooligohidroxi inhibidores de renina.
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten
RU94017664A (ru) Соединения, используемые в качестве антагонистов 5-нт-рецепторов, способ получения, фармацевтическая композиция
GT199100061A (es) Derivados de acido acetico
EA200300782A1 (ru) Пролекарства возбуждающих аминокислот
DOP2001000245A (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso.
MY135855A (en) "pyrrolopyrimidinone derivatives, process of preparation and use"
SE9704835D0 (sv) New compound

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS INC. (N.D.GES.D. STAATES PENNSYLVANIA), GR

8327 Change in the person/name/address of the patent owner

Owner name: AVENTISUB II INC., GREENVILLE, DEL., US